February 17, 2014 3:57pm

Capricor Therapeutics, Inc. (OTCQB: CAPR) is a heart failure biotechnology company focused on the advancement of stem cell-based therapies for prevention and treatment of heart damage associated with cardiac failure.  The company was formed in November, 2013 through the merger of Capricor Inc., a privately-held clinical stage biotechnology company developing cardiac-derived stem cell therapeutics to repair damaged heart muscle, and Nile Therapeutics Inc., a clinical stage biopharmaceutical company developing innovative products for the treatment of heart disease.    The combined entity is strategically positioned at the forefront of one of the highest demand fields within cardiovascular medicine today:  heart failure, a condition that costs the U.S healthcare system almost $40 billion annually.

Members only. Please login.